Development of Second-Generation CDK2 Inhibitors for the Prevention of Cisplatin-Induced Hearing Loss

Robert A. Hazlitt, Tal Teitz, Justine D. Bonga, Jie Fang, Shiyong Diao, Luigi Iconaru, Lei Yang, Asli N. Goktug, Duane G. Currier, Taosheng Chen, Zoran Rankovic, Jaeki Min, Jian Zuo

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


There are currently no FDA-approved therapies to prevent the hearing loss associated with the usage of cisplatin in chemotherapeutic regimens. We recently demonstrated that the pharmacologic inhibition with kenpaullone or genetic deletion of CDK2 preserved hearing function in animal models treated with cisplatin, which suggests that CDK2 is a promising therapeutic target to prevent cisplatin-induced ototoxicity. In this study, we identified two lead compounds, AT7519 and AZD5438, from a focused library screen of 187 CDK2 inhibitors, performed in an immortalized cell line derived from neonatal mouse cochleae treated with cisplatin. Moreover, we screened 36 analogues of AT7519 and identified analogue 7, which exhibited an improved therapeutic index. When delivered locally, analogue 7 and AZD5438 both provided significant protection against cisplatin-induced ototoxicity in mice. Thus, we have identified two additional compounds that prevent cisplatin-induced ototoxicity in vivo and provided further evidence that CDK2 is a druggable target for treating cisplatin-induced ototoxicity.

Original languageEnglish (US)
Pages (from-to)7700-7709
Number of pages10
JournalJournal of Medicinal Chemistry
Issue number17
StatePublished - Sep 13 2018
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Drug Discovery


Dive into the research topics of 'Development of Second-Generation CDK2 Inhibitors for the Prevention of Cisplatin-Induced Hearing Loss'. Together they form a unique fingerprint.

Cite this